SCHEMBL19092433

SCHEMBL19092433

c1ccc(-n2ncc3c(-c4ccc(C5CCNCC5)cc4)cccc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KHK P50053 4/20 0.46
▸ CYP17A1 P05093 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ SLC18A3 Q16572 1/20 0.43
▸ SIGMAR1 Q99720 1/20 0.43
▸ ACVR1 Q04771 3/20 0.40
▸ BMPR1B O00238 2/20 0.40
▸ BMPR1A P36894 2/20 0.40
▸ ACVR1B P36896 2/20 0.40
▸ ACVRL1 P37023 2/20 0.40
▸ HTR6 P50406 1/20 0.39
▸ RET P07949 1/20 0.38
▸ GABRA1 P14867 3/20 0.38
▸ GABRB2 P47870 3/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ PLAT P00750 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ PTK2 Q05397 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30716966 0.79 CYP1A2 (0.61) CYP17A1CYP1A2ALDH1A1
SCHEMBL26970884 0.79 CYP1A2 (0.61) CYP17A1CYP1A2ALDH1A1
SCHEMBL20598022 0.78 CCR1 (0.38) ACVR1HTR6PLATJAK3PTK2
SCHEMBL20025760 0.78 ACVR1 (0.33) KHKCYP17A1CYP1A2ACVR1BMPR1B
SCHEMBL31745021 0.78 CCR1 (0.38) ACVR1HTR6PLATJAK3PTK2
SCHEMBL6373488 0.69 SLC18A3 (0.76) SLC18A3SIGMAR1GABRA1GABRB2
SCHEMBL22051953 0.69 SLC18A3 (0.76) SLC18A3SIGMAR1GABRA1GABRB2
SCHEMBL23711766 0.65 KHK (0.62) KHKALDH1A1
SCHEMBL31279404 0.65 KHK (0.62) KHKALDH1A1
SCHEMBL4574 0.65 SLC18A3 (1.00) SLC18A3SIGMAR1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017114497-A1 IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY NOVARTIS AG (CH) 2017-07-06 — — WO disclosed
Send feedback